Search

Search Constraints

You searched for: Author/Creator Fierlbeck, Gerhard

Search Results

1. Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis. Issue 4 (3rd January 2014)

2. European Guidelines (S1) on the use of high‐dose intravenous immunoglobulin in dermatology. (30th December 2016)

3. Europäische Leitlinien (S1) für die Anwendung von hochdosierten intravenösen Immunglobulinen in der Dermatologie. (18th February 2017)

4. Europäische Leitlinien (S1) für die Anwendung von hochdosierten intravenösen Immunglobulinen in der Dermatologie. (February 2017)

5. Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis. (25th October 2017)

6. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Issue 10038 (25th June 2016)

7. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). Issue 2 (24th October 2017)

8. The sentinel lymph node spread determines quantitatively melanoma seeding to non-sentinel lymph nodes and survival. (March 2018)